EUVIMEDEUVIMED entdecken
Crossref

The miR-338-5p/METTL3 axis regulates m6A modification to inhibit tumor progression in triple-negative breast cancer

Wen-Jia Chen, Ya Xu, Yang-Zheng Lan, Xin-Ning Yu, Hua-Tao Wu, Jing Liu

Clinical and Translational Oncology · 20.08.2026

DOI: 10.1007/s12094-026-04534-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Oncology, online erschienen am 20.08.2026. Verfasst von Wen-Jia Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Breast Center, Cancer Hospital of Shantou University Medical College, Shantou, 515041, China. Die Arbeit nennt 43 Literaturangaben. Gefördert von: Innovative Research Group Project of the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer characterized by poor prognosis and limited therapeutic options. METTL3, a critical m6A RNA methyltransferase, has been implicated in tumor progression. However, its molecular mechanisms in TNBC remain to be fully elucidated. METHODS: METTL3 expression was analyzed using public databases, cell lines, and clinical samples. Functional assays were performed on TNBC cells following METTL3 knockdown or overexpression. RNA m6A levels were quantified to assess the methyltransferase activity of METTL3. MiR-338-5p was identified as a potential upstream regulator of METTL3 via prediction tools, and validated by luciferase assays. In vivo relevance was assessed using xenograft mouse models. RESULTS: METTL3 was upregulated in TNBC cell lines and tumor tissues, correlating with larger tumor size and poorer prognosis. METTL3 knockdown suppressed proliferation, migration, invasion, and EMT, and reduced global RNA m6A modification. METTL3 overexpression enhanced these malignant traits and increased m6A levels. MiR-338-5p directly bound to the 3'UTR of METTL3 and suppressed METTL3 protein expression without affecting mRNA levels. Overexpression of miR-338-5p decreased RNA m6A levels and attenuated TNBC aggressiveness, effects that were reversed by METTL3 restoration, confirming a functional miR-338-5p/METTL3/m6A axis. In vivo, METTL3 overexpression promoted tumor growth and proliferation in xenograft models, whereas knockdown suppressed these effects. CONCLUSION: METTL3 functions as an oncogenic driver in TNBC by promoting proliferation, invasion, and EMT through an m6A-dependent mechanism. This study reveals post-transcriptional regulation of METTL3 by miR-338-5p in TNBC. Targeting this distinct regulatory axis represents a promising therapeutic strategy for TNBC.

Schlagwörter

Stichwörter der Autor:innen

M6A methylationMETTL3MiR-338-5pTriple-negative breast cancer

Autor:innen und Institutionen

  • The Breast Center, Cancer Hospital of Shantou University Medical College, Shantou, 515041, China.
  • Department of Physiology, Shantou University Medical College, Shantou, 515041, China.
  • Department of Radiation Oncology, Shenshan Medical Centre, Memorial Hospital of Sun Yat-Sen University, Shanwei, 516600, China.
  • Department of General Surgery, the First Affiliated Hospital of Shantou University Medical College, Shantou, 515041, China.
  • Department of General Surgery, the First Affiliated Hospital of Shantou University Medical College, Shantou, 515041, China. htwu@stu.edu.cn.
  • The Breast Center, Cancer Hospital of Shantou University Medical College, Shantou, 515041, China. jliu12@stu.edu.cn.

Förderung

  • Innovative Research Group Project of the National Natural Science Foundation of China

Zitieren

APA

Chen, W. J., Xu, Y., Lan, Y. Z., Yu, X. N., Wu, H. T., & Liu, J. (2026). The miR-338-5p/METTL3 axis regulates m6A modification to inhibit tumor progression in triple-negative breast cancer. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-026-04534-y

Vancouver

Chen WJ, Xu Y, Lan YZ, Yu XN, Wu HT, Liu J. The miR-338-5p/METTL3 axis regulates m6A modification to inhibit tumor progression in triple-negative breast cancer. Clinical and Translational Oncology. 2026. doi:10.1007/s12094-026-04534-y

BibTeX
@article{Chen2026,
  author = {Chen, Wen-Jia and Xu, Ya and Lan, Yang-Zheng and Yu, Xin-Ning and Wu, Hua-Tao and Liu, Jing},
  title = {The miR-338-5p/METTL3 axis regulates m6A modification to inhibit tumor progression in triple-negative breast cancer},
  journal = {Clinical and Translational Oncology},
  year = {2026},
  doi = {10.1007/s12094-026-04534-y}
}
Kostenlos starten →